Polarean Imaging enters strategic partnership with VIDA Diagnostics

The AIM-traded firm said the collaboration was intended to bolster the capabilities of Polarean's xenon 129 MRI platform, with the aim of increasing its use in both clinical settings and research.

It said that, with a track record of supporting more than 1,000 clinical and research locations globally, VIDA was recognised for its cloud-native, AI-enabled imaging management platform.

The platform both drives standardisation and operational efficiency in clinical trial imaging, and also boasts a distinct orchestration engine.

Polarean said the engine integrates and fine-tunes various clinical algorithms, making top-tier imaging biomarkers readily accessible.

Such advancements facilitate the seamless integration of those biomarkers into clinical trials, research initiatives, and routine clinical care workflows.

The partnership between the two companies would focus on incorporating the xenon 129 MRI process into the broader clinical care continuum.

That effort would lay the groundwork for a clinical trial network dedicated to drug and device development under pharmaceutical sponsorship.

Polarean said the collaboration aimed to standardise xenon 129 MR image acquisition and data-sharing methods, and was also poised to generate automated image processing workflows and algorithms.

As a part of the initiative, the pair would work towards diversifying the applications of xenon 129 MRI in lung imaging services.

They would also explore new potential indications and biomarkers in populations that currently have unaddressed medical needs.

“Polarean continues to cultivate partnerships with entities that enhance our core capabilities,” said Polarean chief executive officer Christopher von Jako.

“We are excited to form this partnership with VIDA, a world-renowned organisation in the field of lung imaging software platform solutions and biomarker development, to capitalise on their complementary expertise.

“Furthermore, this partnership perfectly aligns with our objective of extending the reach of Xenoview MRI, to provide tools to physicians that treat patients suffering from chronic lung disease.”

At 1305 BST, shares in Polarean Imaging were down 1.69% at 11.31p.

Reporting by Josh White for Sharecast.com.